PDT In PDT, revenue was JPY 784.2 billion (JPY +109.7 billion and +16.3% AER, +9.8% CER). Aggregate sales of immunoglobulin products were JPY 576.0 billion (JPY +90.3 billion and +18.6% AER, +11.9% CER). Sales of each of our three global immunoglobulin brands experienced double digit percentage sales growth, due to continued strong demand globally and growing supply, as well as favorable foreign exchange rates. Those include GAMMAGARD LIQUID/KIOVIG (for the treatment of primary immunodeficiency (“PID”) and multifocal motor neuropathy (“MMN”)), and subcutaneous immunoglobulin therapies (CUVITRU and HYQVIA), sales of which are growing at a fast pace due to their benefit to patients and convenience in administration compared to intravenous therapies. Aggregate sales of albumin products including HUMAN ALBUMIN and FLEXBUMIN (both primarily used for hypovolemia and hypoalbuminemia) were JPY 101.3 billion (JPY +7.0 billion and +7.4% AER, +2.2% CER). The increase was primarily driven by favorable foreign exchange rates
CSL Price at posting:
$279.73 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)